Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): 'Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling'

The article discusses Jim Cramer's investing experiences and emphasizes the importance of starting early in the stock market. It also highlights Regeneron Pharmaceuticals Inc. as a strong investment option with a solid pipeline and growth potential, ranking 16th on Cramer's list.